CC-1065 (NSC-298223), A NEW ANTI-TUMOR ANTIBIOTIC PRODUCTION, INVITRO BIOLOGICAL-ACTIVITY, MICROBIOLOGICAL ASSAYS AND TAXONOMY OF PRODUCING MICROORGANISM
CC-1065 (NSC-298223), A NEW ANTI-TUMOR ANTIBIOTIC PRODUCTION, INVITRO BIOLOGICAL-ACTIVITY, MICROBIOLOGICAL ASSAYS AND TAXONOMY OF PRODUCING MICROORGANISM
复制标题
DOI：
10.7164/antibiotics.31.1211
复制
发表时间：
1978-01-01
影响因子：
3.3
通讯作者：
MARTIN, DG
中科院分区：
文献类型：
--
作者：
HANKA, LJ;DIETZ, A;MARTIN, DG
从新西兰链霉菌Streptomyces zelensis sp. nov.的发酵液中产生一种新的抗肿瘤抗生素，该抗生素在极低浓度下具有生物活性。在40 pg/ml时，在试管稀释试验中，它抑制了培养物中[小鼠白血病] L1210细胞90%的生长。对革兰氏阳性细菌的最小抑制浓度为1 - 10 ng/ml，而对革兰氏阴性细菌和真菌的这些值大多低于1 μ g/ml。使用枯草芽孢杆菌的微生物测定法可检测1 - 2 ng/ml的浓度。
A new antitumor antibiotic is produced in fermentation liquors of Streptomyces zelensis sp. nov. The antibiotic is biologically active at extremely low concentrations. At 40 pg/ml, it inhibited 90% of the growth of [mouse leukemia] L1210 cells in culture in tube dilution assays. The minimal inhibitory concentrations against gram-positive bacteria is 1-10 ng/ml, while these values for gram-negative bacteria and fungi are mostly under 1 .mu.g/ml. A microbiological assay with Bacillus subtilis can detect concentrations of 1-2 ng/ml.